DA32 Life Science Tech Acquisition Corp.
DALS
NASDAQ Capital Market10.30
USD
-0.02
- -
CIK
0001863294
ISIN
US23312M1062
CUSIP
23312M106
Return %
Stock
S&P500
1Y
5.97
18.21
3Y
4.67
64.38
5Y
4.67
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Steven Kafka
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 345 Park Avenue South New York City NY United States of America 10010
- IPO Date
- Jul 28, 2021
- CIK
- 0001863294
- Similar Companies
- Business
- DA32 Life Science Tech Acquisition Corp. (NASDAQ: DALS) operates as a blank check company whose sole purpose centers on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses; targets include biotechnology and life science infrastructure sectors such as life sciences tools, diagnostics, synthetic biology, and data and analytics platforms. Incorporated in 2021 and headquartered at 345 Park Avenue South, 12th floor, New York, New York, the company conducts no significant operations or revenue generation prior to completing an initial business combination. Sponsored by affiliates of Deerfield Management Company, ARCH Venture Partners, and Section 32, it raised $200 million in its July 2021 initial public offering of 20 million Class A common shares at $10.00 per share, underwritten by J.P. Morgan and Cowen. In July 2023, facing expiration of its charter timeframe without identifying a suitable target, DA32 announced redemption of all outstanding public shares effective July 28, 2023, at approximately $10.31 per share from its trust account, followed by Nasdaq delisting via Form 25, SEC deregistration via Form 15, and full liquidation within ten business days thereafter. Initial shareholders waived redemption rights on their Class B founder shares during this wind-down process. As of late 2025, no post-liquidation revival or new activities appear in public records.
Deerfield Management Company, L.P.
DA32 Life Science Tech Acquisition Corp. Announces Redemption of Shares
DA32 Life Science Tech Acquisition Corp., Sponsored by Deerfield, Arch Venture Partners and Section 32, Announces Pricing of $200 Million Initial Public Offering